Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

Why did Tesla shares drop during Musk-Trump feud? How did Trump-Musk spat impact Tesla stock? What caused recent surge in oil prices? Why is the Supreme Court allowing DOGE access to Social Security data? How are US-China trade talks affecting markets? What risks do tariffs pose to US inflation? Why did Tesla’s Optimus robot VP leave?

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

benzinga.com/news/health-care/25/06/45817049/arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-der

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced it will present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.
Among them is new data from the INTEGUMENT-OLE study, showing that investigational ZORYVE cream 0.05% is safe and effective long-term for…

This story appeared on benzinga.com, 2025-06-06 15:11:50.